These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28317807)

  • 21. Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
    Dinakaran M; Senthilkumar P; Yogeeswari P; China A; Nagaraja V; Sriram D
    Bioorg Med Chem; 2008 Mar; 16(6):3408-18. PubMed ID: 18304818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
    Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
    Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs.
    Khare G; Kar R; Tyagi AK
    PLoS One; 2011; 6(7):e22441. PubMed ID: 21818324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.
    Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M
    J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.
    Guillemont J; Meyer C; Poncelet A; Bourdrez X; Andries K
    Future Med Chem; 2011 Sep; 3(11):1345-60. PubMed ID: 21879841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug design and identification of potent leads against mycobacterium tuberculosis thymidine monophosphate kinase.
    Van Calenbergh S; Pochet S; Munier-Lehmann H
    Curr Top Med Chem; 2012; 12(7):694-705. PubMed ID: 22283813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
    Gasse C; Huteau V; Douguet D; Munier-Lehmann H; Pochet S
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1057-61. PubMed ID: 18058536
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
    Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis.
    Taneja NK; Tyagi JS
    J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
    Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
    J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis.
    Claes P; Cappoen D; Uythethofken C; Jacobs J; Mertens B; Mathys V; Verschaeve L; Huygen K; De Kimpe N
    Eur J Med Chem; 2014 Apr; 77():409-21. PubMed ID: 24681334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of anti-tuberculosis activity in some folklore plants by radiometric BACTEC assay.
    Gupta VK; Shukla C; Bisht GR; Saikia D; Kumar S; Thakur RL
    Lett Appl Microbiol; 2011 Jan; 52(1):33-40. PubMed ID: 21114505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1-(Piperidin-3-yl)thymine amides as inhibitors of
    Jian Y; Risseeuw MDP; Froeyen M; Song L; Cappoen D; Cos P; Munier-Lehmann H; van Calenbergh S
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1730-1739. PubMed ID: 31822127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Mycobacterium smegmatis transposon mutant array for characterising the mechanism of action of tuberculosis drugs: Findings with isoniazid and its structural analogues.
    Campen RL; Ackerley DF; Cook GM; O'Toole RF
    Tuberculosis (Edinb); 2015 Jul; 95(4):432-9. PubMed ID: 25936537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insight into the structural requirements of aminopyrimidine derivatives for good potency against both purified enzyme and whole cells of M. tuberculosis: combination of HQSAR, CoMSIA, and MD simulation studies.
    Punkvang A; Hannongbua S; Saparpakorn P; Pungpo P
    J Biomol Struct Dyn; 2016 May; 34(5):1079-91. PubMed ID: 26156406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
    Familiar O; Munier-Lehmann H; Negri A; Gago F; Douguet D; Rigouts L; Hernández AI; Camarasa MJ; Pérez-Pérez MJ
    ChemMedChem; 2008 Jul; 3(7):1083-93. PubMed ID: 18418833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
    Dixit PP; Dixit PP; Thore SN
    Eur J Med Chem; 2016 Jan; 107():38-47. PubMed ID: 26562541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.
    Palencia A; Li X; Bu W; Choi W; Ding CZ; Easom EE; Feng L; Hernandez V; Houston P; Liu L; Meewan M; Mohan M; Rock FL; Sexton H; Zhang S; Zhou Y; Wan B; Wang Y; Franzblau SG; Woolhiser L; Gruppo V; Lenaerts AJ; O'Malley T; Parish T; Cooper CB; Waters MG; Ma Z; Ioerger TR; Sacchettini JC; Rullas J; Angulo-Barturen I; Pérez-Herrán E; Mendoza A; Barros D; Cusack S; Plattner JJ; Alley MR
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6271-80. PubMed ID: 27503647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knowledge based identification of potent antitubercular compounds using structure based virtual screening and structure interaction fingerprints.
    Kumar A; Chaturvedi V; Bhatnagar S; Sinha S; Siddiqi MI
    J Chem Inf Model; 2009 Jan; 49(1):35-42. PubMed ID: 19063713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
    Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
    Biochem Biophys Res Commun; 2014 Apr; 446(4):916-20. PubMed ID: 24642256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.